These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 24206017)

  • 1. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
    Gandhi AK; Mendy D; Waldman M; Chen G; Rychak E; Miller K; Gaidarova S; Ren Y; Wang M; Breider M; Carmel G; Mahmoudi A; Jackson P; Abbasian M; Cathers BE; Schafer PH; Daniel TO; Lopez-Girona A; Thakurta A; Chopra R
    Br J Haematol; 2014 Jan; 164(2):233-44. PubMed ID: 24206017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
    Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
    Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
    Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
    Zhu YX; Kortuem KM; Stewart AK
    Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
    Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
    Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide.
    Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R
    Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical significance of cereblon expression in multiple myeloma.
    Schuster SR; Kortuem KM; Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Ahmann G; Kumar S; Rajkumar SV; Mikhael J; Laplant B; Champion MD; Laumann K; Barlogie B; Fonseca R; Bergsagel PL; Lacy M; Stewart AK
    Leuk Res; 2014 Jan; 38(1):23-8. PubMed ID: 24129344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.
    Lu G; Middleton RE; Sun H; Naniong M; Ott CJ; Mitsiades CS; Wong KK; Bradner JE; Kaelin WG
    Science; 2014 Jan; 343(6168):305-9. PubMed ID: 24292623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.
    Eichner R; Heider M; Fernández-Sáiz V; van Bebber F; Garz AK; Lemeer S; Rudelius M; Targosz BS; Jacobs L; Knorn AM; Slawska J; Platzbecker U; Germing U; Langer C; Knop S; Einsele H; Peschel C; Haass C; Keller U; Schmid B; Götze KS; Kuster B; Bassermann F
    Nat Med; 2016 Jul; 22(7):735-43. PubMed ID: 27294876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
    Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
    BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
    Ren Y; Wang M; Couto S; Hansel DE; Miller K; Lopez-Girona A; Bjorklund CC; Gandhi AK; Thakurta A; Chopra R; Breider M
    Appl Immunohistochem Mol Morphol; 2016; 24(10):695-702. PubMed ID: 26186254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.
    Greenberg AJ; Walters DK; Kumar SK; Rajkumar SV; Jelinek DF
    Eur J Haematol; 2013 Dec; 91(6):504-13. PubMed ID: 23992230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
    Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
    Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
    Ocio EM; Fernández-Lázaro D; San-Segundo L; López-Corral L; Corchete LA; Gutiérrez NC; Garayoa M; Paíno T; García-Gómez A; Delgado M; Montero JC; Díaz-Rodríguez E; Mateos MV; Pandiella A; Couto S; Wang M; Bjorklund CC; San-Miguel JF
    Leukemia; 2015 Mar; 29(3):705-14. PubMed ID: 25102946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARID2 is a pomalidomide-dependent CRL4
    Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
    Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Thalidomide, cereblon and multiple myeloma].
    Ogura T
    Nihon Rinsho; 2015 Jan; 73(1):149-55. PubMed ID: 25626321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.